**Figure 1**

**Treatment Groups**

- **Total N = 462** (blinded sample size/c randomisation after 33% to 40% enrolled).
- **Randomised 1:1:1**
  - 2000 μg MED4893 (a = 154) (can be adjusted to 3000 μg based on interim PK results)
  - 5000 μg MED4893 (a = 154)
  - Placebo (a = 154)

**Follow-up Period (Day)**

- Investigational product administration, single intravenous (IV) dose
- Interim analysis: pharmacokinetics (PK), after at least 10 subjects enrolled in each treatment group
- Futility assessment by independent Data Monitoring Committee (DMC) after 33% to 40% of subjects enrolled
- Stage 1 analysis: efficacy, PK, Anti-drug antibody (ADA), and safety
- Stage 2 analysis: Long-term safety follow-up

**Methods of Using Anti-Alpha Toxin Antibody**

**Abstract**

Provided herein are methods of preventing and treating a bacterial infection, e.g., a *Staphylococcus aureus* infection, in a patient, comprising administering to the patient an effective amount of an anti-alpha toxin antibody or an antigen-binding fragment thereof, such as MED4893.
Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

Date of publication of the international search report: 8 June 2017
A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61 K 39/085; C07K 16/12 (201 7.01 )
CPC - A61 K 39/085; C07K 16/1271; C07K 231 7/565; C07K 231 7/76 (201 7.02)

According to International Patent Classification (IPC) or to both national classification and IPC

B. MINIMUM DOCUMENTATION SEARCHED

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2012/109285 A2 (MEDIMMUNE, LLC et al) 16 August 2012 (16.08.2012) entire document</td>
<td>1, 3, 5, 10, 12, 14, 18</td>
</tr>
<tr>
<td>A</td>
<td>WO 2014/074540 A2 (MEDIMMUNE, LLC) 15 May 2014 (15.05.2014) entire document</td>
<td>1-5, 10-14, 18, 19</td>
</tr>
<tr>
<td>A</td>
<td>US 2013/0164308 A1 (RINAT NEUROSCIENCE CORP. et al) 27 June 2013 (27.06.2013) entire document</td>
<td>1-5, 10-14, 18, 19</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

Further documents are listed in the continuation of Box C.

See patent family annex.

Date of the actual completion of the international search 15 March 2017

Date of mailing of the international search report 21 APR 2017

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450
Facsimile No. 571-273-8300

Authorized officer
Blaine R. Copenheaver
PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 6-9, 15-17, 20-52
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: